101918-blog-image-2

Deep MedTech is focused on developing a cloud-based data analysis platform to gain new insights from preclinical imaging data for new drugs and gene therapies in such areas as cancer and heart disease. The use of A.I. in drug and gene therapy research could help speed up development of novel products to market.

Contact us to discuss collaboration

Located in New York City, Deep MedTech is a wholly-owned subsidiary of AI VentureTech, Inc.

 


AI in healthcare is currently geared towards improving patient outcomes, aligning the interests of various stakeholders, and reducing healthcare costs.


AI FOR MEDICAL OBJECT DETECTION

Deep MedTech platform for AI Object Detection will enable doctors, academic researchers or OEM application builders to use their own AI/ML models real-time over an ultra low-latency, highly reliable and secure Cloud Edge network.

  •  Gets real time inferences from an edge based AI model and highlights objects of interest during a procedure.
  • Allows users to easily power their AI model over a sophisticate edge network and integrate them with enterprise applications. It specializes larger models optimizing them to real-time performance.
  • Labeling to help label large data sets faster, and enable annotations to data sets and get them reviewed faster.

AI IN GENE THERAPY

As artificial intelligence (AI) and machine learning (ML) play a greater role in gene therapy, the old one-size-fits-all medicine seems to be on its way out. Developments in “gene editing” mean scientists are now altering the DNA of living patients, and using AI which can help boost the precision of the editing process.

Deep MedTech will look to utilize data derived from global gene expression studies, and epigenetic experiments, to predict which genomic sequences are involved in cell type-specific regulation of gene expression.


 

HOW TO INVEST IN COMPANY

Investment opportunities in Deep MedTech are currently available to ‘accredited’ and institutional investors only, as defined by the SEC. If you are an ‘accredited investor’ and would like to learn more on how to invest in the company, please register to our free online investor network

Share